readthroughSign in
CompanyABOSNasdaqNewton, MA

Acumen Pharmaceuticals

Acumen Pharmaceuticals develops monoclonal antibodies targeting toxic soluble amyloid beta oligomers for Alzheimer's disease treatment.

10-QNov 5Latest SEC filing
Nov 5Latest story